DFE Pharma, a producer of excipients for pharma- and nutraceutical applications, has announced the appointment of Martti Hedman as CEO. Hedman will succeed Bas van Driel and assume responsibilities on 14 February.
Hedman has many years of business leadership experience in the pharma industry, having held executive positions in the United States, United Kingdom, Germany, and Finland. Formerly, he was CEO of Colorcon, a global designer and developer of specialty excipients for solid oral dosages for the pharmaceutical and nutritional industries.
Speaking on behalf of the Governance Board, Herman Ermens of Royal FrieslandCampina, said: “We are very pleased to welcome Martti Hedman to DFE Pharma, an influential and decisive leader with a history of success. Martti will bring a wealth of international experience in the pharma industry as well as a broad range of both industry and customer relationships. We are confident that Martti is very well-placed to take the business to the next level as a global excipient company.”
Hedman said: “I am excited to join DFE Pharma as its new CEO. The company is a global market leader in its excipient categories. I am looking forward to working with all my new colleagues and taking the company to the next phase. I am especially pleased to know that DFE Pharma plays a key role in the COVID-19 therapies – both in vaccines and in solid oral dosage forms.”
